Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice

Written by: Joshua D. Levinson, MD November 2020 Maloney MH, Payne SR, Herrin J, et al. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmol. Published online August 2020. doi:10.1016/j.ophtha.2020.07.062 Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in the treatment of multiple […]

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial

November 2020 Lim TH, Lai TYY, Takahashi K et al. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. Sept 2020; 138(9): 935-942. Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration characterized by aneurysmal polypoidal lesions best imaged with […]

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial

Written by: Katherine E. Talcott, MD October 2020 Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA, C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial, Ophthalmology (2020), doi: https://doi.org/10.1016/j.ophtha.2020.08.027. While there are multiple treatment […]

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

Written by: Maxwell S. Stem, MD September 2020 Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration (The STAIRWAY Phase 2 Randomized Clinical Trial). JAMA Ophthalmol. 2020;138(9):964-972. […]

Timing of Peak Vision Gains in Patients with Neovascular Age-related Macular Degeneration Treated with Ranibizumab

Written by: Mehnaz Khan, MD September 2020 Khurana RN, Chang L, Day BM, Ghanekar A, Stoilov I. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. Ophthalmol Retina. 2020;4(8):760-766. doi:10.1016/j.oret.2020.02.011 It is widely accepted that the treatment of neovascular age-related macular degeneration (nAMD) includes intravitreal injections of anti-vascular endothelial growth […]

Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Plana Vitrectomy Sclerotomy Nomogram

Written by: Edward H. Wood, MD September 2020 Wright LM, Harper A, Chang EY. Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Plana Vitrectomy Sclerotomy Nomogram. Ophthalmol Retina. 2018 Dec;2(12):1227-1234. doi: 10.1016/j.oret.2018.06.008. Epub 2018 Aug 16. This excellent paper provides important surgical data for retina specialists taking care of pediatric patients. A relatively larger […]

Primary Retinal Detachment Outcomes Study Report Number 2: Phakic Retinal Detachment Outcomes

Written by: Brian C. Toy, MD September 2020 EH Ryan, CM Ryan, NJ Forbes, et al. Primary Retinal Detachment Outcomes Study Report Number 2: Phakic Retinal Detachment Outcomes. Ophthalmology. 2020 Aug;127(8):1077-1085. doi: 10.1016/j.ophtha.2020.03.007. Epub 2020 Mar 9. The Primary Retinal Detachment Outcomes (PRO) Study assessed anatomic and visual outcomes among contemporary RRD cases performed employing SB, PPV, […]